Sponsor or institution

Clinical trials and research at Chongqing Precision Biotech Co., Ltd

• 25Clinical trials
• 1Country

Newest trials

All recruiting trials (25)

• In Vivo PICX CAR-T Therapy for Relapsed or Refractory Multiple Myeloma

  A single-arm study is testing an in vivo CAR-T cell therapy (PICX Injection) to see if it is safe and can help people with relapsed or refractory multiple myeloma.

  Recruiting Phase 1 Chongqing Precision Biotech Co., Ltd · Kunming, Yunnan · NCT07715630

• In‑body CAR‑T generation with PIC1 injection for relapsed or refractory B‑cell non‑Hodgkin lymphoma.

  This will try a single intravenous PIC1 injection to create CAR‑T cells inside the body for adults with relapsed or refractory B‑cell non‑Hodgkin lymphoma.

  Recruiting Phase 1 Chongqing Precision Biotech Co., Ltd · Wuhan, Hubei · NCT07456371

• CD19 CAR-T (PTOC1) therapy for refractory systemic lupus erythematosus

  This study will try a fast-made CD19 CAR-T cell treatment called PTOC1 in people aged 5 and older whose lupus has not improved with high-dose steroids and multiple immunosuppressive drugs.

  Recruiting Phase 1 Chongqing Precision Biotech Co., Ltd · Chongqing · NCT07403097

• Ultra-fast autologous CD19 CAR-T therapy for refractory SLE

  This trial will try ultra-fast autologous CD19 CAR-T cells to see if they can control disease in adults with refractory systemic lupus erythematosus.

  Recruiting Phase 1 Chongqing Precision Biotech Co., Ltd · Nanjing, Jiangsu · NCT07331467

• Ultra-fast BCMA/CD70 CAR-T therapy for refractory lupus

  This trial will test ultra-fast BCMA/CD70 CAR-T cell therapy in adults with systemic lupus erythematosus that has not responded to standard treatments.

  Recruiting Phase 1 Chongqing Precision Biotech Co., Ltd · Nanjing, Jiangsu · NCT07318259

• In vivo CAR-T therapy for relapsed or refractory B‑cell leukemias, lymphomas, and multiple myeloma

  This trial will try a single in‑body (intravenous) CAR‑T infusion to treat adults with relapsed or refractory B‑cell acute lymphoblastic leukemia, B‑cell non‑Hodgkin lymphoma, or multiple myeloma.

  Recruiting Phase 1 Chongqing Precision Biotech Co., Ltd · Kunming, Yunnan · NCT07239323

• BCMA/CD70-directed CAR-T for children with hard-to-treat rheumatic diseases

  This trial will try a BCMA/CD70-directed CAR-T therapy in children aged 5 and older whose rheumatic diseases have not responded to standard treatments.

  Recruiting Phase 1 Chongqing Precision Biotech Co., Ltd · Hangzhou, Zhejiang · NCT07184450

• CEA-targeted CAR-T for advanced CEA-positive solid tumors

  This trial will try CEA-targeted CAR-T cell infusions in adults with advanced CEA-positive cancers (such as colorectal, gastric, esophageal, lung, or pancreatic cancer) to see if the treatment is safe and helps control the disease.

  Recruiting Phase 1 Chongqing Precision Biotech Co., Ltd · Hefei, Anhui · NCT07179692

• Targeted CAR-T Immunotherapy for Advanced Lung Cancer

  This study is testing a new CAR-T cell treatment for people with advanced lung cancer to see if it can effectively target and kill cancer cells that have a specific marker.

  Recruiting Phase 1 Chongqing Precision Biotech Co., Ltd · Nanjing, Jiangsu · NCT06992583

• CAR-T therapy targeting a specific tumor marker in advanced lung cancer

  This study is testing a new CAR-T therapy aimed at a specific tumor marker in patients with advanced lung cancer to see if it can help them after other treatments have failed.

  Recruiting Phase 1 Chongqing Precision Biotech Co., Ltd · Wuhan, Hubei · NCT06945523

• CD5-targeted CAR-NK therapy for T-cell cancers

  This study is testing a new type of treatment using special immune cells to see if it can help people with tough-to-treat T-cell cancers feel better when other treatments haven't worked.

  Recruiting Phase 1 Chongqing Precision Biotech Co., Ltd · Wuhan, Hubei · NCT06909474

• CAR-T therapy for advanced lung cancer targeting CEA

  This study is testing a new CAR-T therapy for people with advanced lung cancer that targets a specific marker to see if it can help those who haven't improved with regular treatments.

  Recruiting Phase 1 Chongqing Precision Biotech Co., Ltd · Shanghai · NCT06903117

• CD19-targeted CAR-T (MC-1-50) for adults with refractory SLE

  This trial will try a rapid-manufactured CD19-directed CAR-T cell therapy called MC-1-50 in adults whose SLE has not responded to standard treatments.

  Recruiting at 2 sites Phase 1 Chongqing Precision Biotech Co., Ltd · Hefei, Anhui and 1 other locations · NCT06892145

• Targeting CEA in Advanced Lung Cancer with CAR-T Therapy

  This study is testing a new CAR-T therapy for people with advanced lung cancer to see if it can help them after other treatments have failed.

  Recruiting Phase 1 Chongqing Precision Biotech Co., Ltd · Wuhan, Hubei · NCT06768151

• CD123-targeted CAR-NK therapy for relapsed/refractory AML or BPDCN

  This study is testing a new treatment using special immune cells to see if it can help people with relapsed or hard-to-treat acute myeloid leukemia or blastic plasmacytoid dendritic cell neoplasm.

  Recruiting Phase 1 Chongqing Precision Biotech Co., Ltd · Wuhan, Hubei · NCT06690827

• Treatment of Refractory Juvenile Dermatomyositis with CD19 Targeted CAR-T Cells

  This study is testing a new CAR-T cell therapy to see if it can help kids with tough-to-treat juvenile dermatomyositis feel better and improve their health.

  Recruiting Phase 1 Chongqing Precision Biotech Co., Ltd · Hangzhou, Zhejiang · NCT06686524

• CD19-targeted CAR-T therapy for treating refractory juvenile dermatomyositis

  This study is testing a new CAR-T therapy for children with tough-to-treat juvenile dermatomyositis to see if it can help improve their condition.

  Recruiting Phase 1 Chongqing Precision Biotech Co., Ltd · Hangzhou, Zhejiang · NCT06569472

• CD70-targeted CAR-T treatment for advanced gynecologic cancer

  This study is testing a new CAR-T treatment that targets CD70 to see if it can help people with advanced gynecologic cancers feel better and improve their outcomes.

  Recruiting Phase 1 Chongqing Precision Biotech Co., Ltd · Wuhu, Anhui · NCT06215950

• Treatment for relapsed B-cell lymphoma using CAR-T cells

  This study is testing a new CAR-T cell therapy to see if it can help people with relapsed B-cell lymphoma feel better and improve their treatment outcomes.

  Recruiting Phase 1 Chongqing Precision Biotech Co., Ltd · Beijing, Beijing Municipality · NCT06180174

• Treatment using CEA-targeted CAR-T cells for advanced solid tumors

  This study is testing a new type of immune therapy using CAR-T cells to see if it can help people with advanced solid tumors that have a specific marker called CEA.

  Recruiting Phase 1 Chongqing Precision Biotech Co., Ltd · Wuhu, Anhui · NCT06126406

• Targeting CEA with CAR-T cells for advanced solid tumors

  This study is testing a new type of CAR-T cell treatment for people with advanced solid tumors to see if it's safe and how well it works.

  Recruiting at 2 sites Phase 1 Chongqing Precision Biotech Co., Ltd · Hangzhou, Zhejiang and 1 other locations · NCT06043466

• Treatment of relapsed or refractory B-ALL in children and adolescents using pCAR-19B

  This study is testing a new CAR T-cell therapy called pCAR-19B to see if it can help children and teens with hard-to-treat B-cell leukemia feel better.

  Recruiting at 16 sites Phase 2 Chongqing Precision Biotech Co., Ltd · Beijing, Beijing Municipality and 15 other locations · NCT05334823

• Treatment using CD19 and CD22 targeted CAR-T cells for relapsed B-ALL

  This study is testing a new CAR-T cell treatment that targets both CD19 and CD22 to see if it can help patients with relapsed or hard-to-treat B-cell acute lymphoblastic leukemia feel better.

  Recruiting Phase 1/2 Chongqing Precision Biotech Co., Ltd · Kunming, Yunnan · NCT04781634

• BCMA-targeted CAR-T cell therapy for relapsed multiple myeloma

  This study is testing a new CAR-T cell therapy that targets a specific protein in people with relapsed multiple myeloma to see if it can help them when other treatments haven't worked.

  Recruiting Phase 1/2 Chongqing Precision Biotech Co., Ltd · Kunming, Yunnan · NCT04776330

• BCMA-targeted CAR-T cell therapy for multiple myeloma

  This study is testing a new CAR-T cell therapy that targets a specific protein in multiple myeloma to see if it can help patients whose cancer has come back or hasn't responded to other treatments.

  Recruiting Phase 1/2 Chongqing Precision Biotech Co., Ltd · Kunming, Yunnan · NCT04271644

Quick answers

How many clinical trials run by Chongqing Precision Biotech Co., Ltd are recruiting right now?

25, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

All of them have sites in China. Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1: 21, Phase 1/2: 3, Phase 2: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →